Zoetis Inc. (NYSE:ZTS) Stake Increased by Strategic Wealth Partners Ltd.

Strategic Wealth Partners Ltd. increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,024 shares of the company's stock after buying an additional 8,052 shares during the period. Strategic Wealth Partners Ltd.'s holdings in Zoetis were worth $7,922,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Mission Wealth Management LP increased its stake in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares in the last quarter. VeraBank N.A. boosted its position in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC grew its holdings in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Procyon Advisors LLC increased its position in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after buying an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC increased its position in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after buying an additional 64 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $212.75.

Zoetis Trading Down 0.2%

Shares of NYSE ZTS traded down $0.31 during midday trading on Tuesday, hitting $163.63. The stock had a trading volume of 1,780,660 shares, compared to its average volume of 2,512,361. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a market capitalization of $72.85 billion, a price-to-earnings ratio of 29.91, a PEG ratio of 2.78 and a beta of 0.94. The company has a fifty day moving average price of $156.58 and a 200 day moving average price of $165.08.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the previous year, the company posted $1.38 earnings per share. Zoetis's revenue was up 1.4% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.